Regeneron Pharmaceuticals (Nasdaq: $REGN): Melanoma Setback Reopens the 2026 Growth Debate

Piattaforma di trading di Regen Pharmaceuticals con simbolo $REGN e DNA in background.

Regeneron Pharmaceuticals is not a fragile biotech story. It is one of the most successful U.S. biotechnology companies of the last two decades, with a deep research culture, internally built technology platforms, a historic ophthalmology franchise around Eylea, a massive immunology engine through Dupixent with Sanofi, and a growing ambition in oncology. That is exactly why the latest melanoma setback matters. The issue is not whether Regeneron can survive one failed study. The real question is

The Smart Money Is Buying These 3 Small Caps Before Anyone Notices: $IMSR, $BHVN, $AVLN

Grafico con tre simboli di valute istituzionali e testo "Institutional Money is Loading".

Institutional Money Is Loading 3 Small Caps — $IMSR, $BHVN, $AVLN | Merlintrader Merlintrader — Institutional Flows Q1 2026 The Smart Money Is Buying These 3 Small Caps Before Anyone Notices: $IMSR, $BHVN, $AVLN Finviz Elite screener data and recent public-market activity highlight three tickers — $IMSR, $BHVN, $AVLN — where institutional ownership, 13F filings, […]

BriaCell Therapeutics Corp. (Nasdaq: $BCTX): Phase 3 Breast Cancer, ASCO 2026 And A Rapid Pipeline Expansion

Immagine di laboratorio con DNA e cellule tumorali, promuovendo BCTX di BriaCell Therapeutics.

Merlintrader Deep Dive Updated May 18, 2026 Biotech / Immuno-Oncology BriaCell Therapeutics Corp. (Nasdaq: $BCTX): Phase 3 Breast Cancer, ASCO 2026 And A Rapid Pipeline Expansion BriaCell is no longer only a tiny Phase 3 metastatic breast cancer binary. Since the last Merlintrader deep dive, the company has added new clinical sites, reported a larger […]

Fortress Biotech (Nasdaq: $FBIO): Q1 2026 Turns the Story Into a Portfolio-Model Test

Logo di Fortress Biotech con DNA e molecole in sfondo, simbolo di innovazione biotech.

Fortress Biotech is one of the more unusual stories in the U.S. small-cap biotech universe because it should not be analyzed like a normal single-drug development company. FBIO is a biopharma platform that creates, finances, controls or participates in multiple companies and programs, trying to monetize value through product revenue, royalties, milestones, asset sales, equity stakes and strategic transactions. That structure makes the stock more complicated than a classic biotech catalyst trade.

SolarEdge Technologies (Nasdaq: $SEDG): Turnaround, Nexis, Storage and the Profitability Test

SEDG

SolarEdge is no longer just a classic residential solar inverter story. The current investment debate is about whether the company can convert its 2025 restructuring, inventory normalization and product refresh into a durable return to profitable growth. Q1 2026 gave bulls enough material to argue that the worst of the cycle may be behind the company: revenue grew 46% year over year, gross margin held above 20%, free cash flow remained positive, and Q2 guidance pointed to another sequential improvement. But the bear case has not disappeared

Defense Stocks Weekly Recap: Ondas, Karman and Red Cat Show Why the Drone-Defense Trade Is No Longer Just a Theme ($ONDS, $KRMN, $RCAT)

defense recap

This week’s defense tape gave traders a useful reminder: the drone-defense and dual-use aerospace trade is alive, but it is no longer a simple “buy the theme” market. The strongest moves are now being separated by revenue quality, backlog visibility, margin path, balance-sheet needs and whether companies can convert battlefield relevance into funded, repeatable commercial execution.

Microbot Medical (Nasdaq: $MBOT): First LIBERTY Revenue, Real Doctors and the Small-Cap Robotics Test

MBOT may2026

Microbot Medical is not a clean “robotics stock” headline. It is a much more interesting, messier and more human story: a small public medical device company trying to commercialize a remotely operated, single-use robotic system for endovascular procedures, while the market debates whether the first commercial signs are meaningful enough to justify the risk. The company has now reported first-quarter 2026 revenue tied to the limited market release of LIBERTY, says Q2 revenue had already exceeded Q1 revenue by mid-quarter, and has scheduled a May 18 investor call where real physician users of the system are expected to join management.

Arrive AI (Nasdaq: $ARAI): The Microcap Building Smart Delivery Points for Drones, Robots and Real People

ARAI

Arrive AI is the kind of small-cap story that can look almost too simple at first glance: a smart mailbox. But the deeper question is more interesting. If drones, ground robots, autonomous vehicles, couriers, hospitals, retailers and consumers are all supposed to participate in a more automated logistics network, where does the physical handoff actually happen? Arrive AI’s answer is the Arrive Point: a secure, climate-assisted, sensor-rich endpoint designed to receive and transfer goods asynchronously.

AI Infrastructure, Optical Engines and Aviation-Tech Optionality: $DTST, $POET and $JTAI Move Into Focus After May 15 Updates

DTST POET JTAI

Data Storage Corporation, POET Technologies and Jet.AI each delivered May 15 updates that speak to a broader market theme: artificial intelligence is no longer only a software story. It is becoming an infrastructure story, a photonics story, a power-and-data-center story, and in some cases a corporate-transformation story. These three companies sit in different corners of that map. $DTST is trying to build a regulated-industry AI continuity platform on top of a recurring telecom and connectivity base. $POET is trying to become a core optical-engine and wafer-level photonic-integration supplier for AI networks and hyperscale data centers. $JTAI is the most complex and speculative of the three, combining AI cloud infrastructure, data-center power access, a pending aviation merger with flyExclusive, strategic holdings and a SpaceX-linked economic interest.

AI Drones, Quantum Defense and the Commercial Space Race: $SPAI, $QUCY and $LUNR Move Into Focus

SPAI, QUCY, LUNR

Safe Pro Group, Quantum Cyber and Intuitive Machines offer three different ways to read the current convergence of artificial intelligence, drones, defense technology and commercial space. Safe Pro Group is the most numbers-driven update in this group, with record first-quarter revenue, a sharp increase in AI product sales and strong gross margins. Quantum Cyber is the most narrative-driven defense platform story, using the launch of quantum-cyber.ai to frame a broader System-of-Systems strategy across autonomous drones, counter-UAS, EMP-hardened components, autonomous demining and quantum antenna communications. Intuitive Machines is the most mature and institutionally visible company in the group, with record quarterly revenue, positive adjusted EBITDA, a record backlog and full-year guidance that still points to a much larger commercial space business in 2026.

Regulatory Paths, PDUFA Risk and Pivotal Oncology: $ATYR, $BTAI and $MBRX After the May 15 Updates

ATYR,BTAI,MBRX

The final May 15 biotech group is not built around early proof-of-concept excitement. It is built around regulatory execution, pivotal-stage risk and the constant question that follows small and mid-sized biotech companies: can the next regulatory or clinical milestone arrive before financing pressure becomes the dominant market narrative? aTyr Pharma, BioXcel Therapeutics and Moleculin Biotech all issued updates on May 15 that give traders and long-form biotech readers a concrete catalyst map, but each company also comes with a very different risk profile.

Alzheimer’s, RAS Oncology and iNKT Cell Therapy: $ANVS, $IMRX and $INKT Enter the May 15 Biotech Watchlist

ANVS,IMRX,INKT

The May 15 biotech tape delivered another group of earnings and business updates that deserve more than a quick headline scan. Annovis Bio pushed its neurodegenerative disease story forward with a Phase 3 Alzheimer’s update, 85% enrollment in its pivotal Alzheimer’s disease trial, a positive DSMB safety recommendation, a Parkinson’s open-label extension study now 40% enrolled, and an outlined NDA path for buntanetap. Immuneering reported a very different type of update, centered on atebimetinib in pancreatic cancer, an upcoming ASCO oral presentation, a pivotal Phase 3 MAPKeeper 301 trial now recruiting, and a strong cash position of $198.6 million expected to fund operations into 2029. MiNK Therapeutics added a smaller but clinically interesting cell-therapy angle, advancing its off-the-shelf iNKT platform into randomized Phase 2 validation in severe acute lung injury and critical illness, with additional clinical data scheduled for ATS on May 20.

Three Biotech Earnings Reports, Three Different Catalyst Stories: Gene Therapy, Autoimmune Cell Therapy and Oncology in Focus — $RGNX, $CABA, $KPTI

RGNX CABA KPTI

REGENXBIO, Cabaletta Bio and Karyopharm all reported first-quarter 2026 updates on the same day, but the investment debate is not simply about quarterly EPS. The real story is a cluster of catalyst paths: Duchenne gene therapy and AbbVie-partnered retinal disease at REGENXBIO, rese-cel autoimmune cell therapy at Cabaletta, and a selinexor franchise trying to extend beyond multiple myeloma at Karyopharm.